Lupin - Launches Critical for Sustenance of Turnaround
Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio.
334 Views
Lupin - Niche Product Drives Earnings Growth
Motilal Oswal's research report onLupin Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with...
330 Views
Lupin (LPC IN) - Margins to Sustain
Prabhudas Lilladher's research report onLupin We revise our FY25/26E EPS estimates by 2.1%/4.3%, as we factor in higher margins.
162 Views
LUPIN Ltd - Strong Gross Margins
Its revenue increased by 12%, supported by notable improvements in EBITDA margins, resulting in Reported PAT reaching Rs 561 Cr.
198 Views
Lupin Ltd - New Drugs Approvals Will Boost Future Prospects
The combined sales from these three drugs could potentially generate incremental sales of ~$100 Mn per year in the US market.
218 Views